|
 |
|
EDITORIAL |
|
|
|
|
| Year : 2011 | Volume
: 4
| Issue : 2 | Page : 69 |
| |
From the Editor's Desk
Kamini Rao
Editor-in-Chief, Journal of Human, Reproductive Sciences, India
| Date of Submission | 03-Oct-2011 |
| Date of Decision | 03-Oct-2011 |
| Date of Acceptance | 03-Oct-2011 |
| Date of Web Publication | 15-Oct-2011 |
Correspondence Address:
Kamini Rao
Editor-in-Chief, Journal of Human, Reproductive Sciences
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0974-1208.86078
How to cite this article:
Rao K. From the Editor's Desk. J Hum Reprod Sci 2011;4:69 |
As always, I have selected a few articles in the current issue of Journal of Human Reproductive Sciences that I consider warrant mention in this issue's editorial. Ovarian hyperstimulation syndrome, the bane of any assisted reproductive technology program and very often a clinician's nightmare, is an iatrogenic complication of assisted reproduction technology. Pratap Kumar and co-workers have recommended a series of measures that can be initiated and precautions that can be exercised to ensure a good prognosis for patients.
The need for a quality-of-life measure for infertility has not been fully met in most parts of the world. In India it is at best a poorly researched area. The various causes of infertility, the multitude of treatment attempts required, and the cost and length of the treatment takes a tremendous toll on the physical and mental health of women. Sameer Valsangkar and his group have carried out a study to measure and compare the impact of infertility on marital adjustment, sexual functioning, quality of life, and the acceptability of various treatment modalities in infertility.
A study by Mohammad Hasan Sheikhha to investigate the association between follicle-stimulating hormone receptor (FSHR) gene polymorphism and the outcomes of controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer has shown that FSHR polymorphism is correlated with response to ovarian stimulation. These findings should, however, be confirmed with larger studies, which will increase its significance.
Dhaliwal and co-workers have tried to show that tamoxifen, an ovulation induction drug, due to its favorable effect on the cervical mucus and endometrium, may be a better choice in patients with polycystic ovarian syndrome, who fail to either ovulate or conceive with clomiphene. Moreover, unlike clomiphene it does not appear to be associated with an increased risk of ovarian or endometrial cancer.
case report on primary abdominal pregnancy following intrauterine insemination and a few interesting letters to the editor make up the rest of this issue.
|
